DRG harvested from six animals/group were employed to assess differences in the immunolocalization of GFAP, a marker of glial activation widely employed in the study of CNS and PNS diseases, between PTX or CDDP-treated animals and their respective controls (vehicle-treated). This evidence concerns the gene GFAP and peripheral nervous system disorder.